Researchers from MIT and Novo Nordisk have developed an innovative microjet system to deliver drugs directly into the gastrointestinal tract, offering a needle-free alternative for administering macromolecules like insulin and RNA. Inspired by cephalopod jet propulsion, the device delivers high-pressure drug jets into specific gastrointestinal regions, improving absorption and addressing limitations of traditional injections.
As reported by news-medical.net, the system includes four configurations: two autonomous devices (MiDeRadAuto, MiDeAxAuto) and two endoscopic-guided models (MiDeRadEndo, MiDeAxEndo), tailored for different gastrointestinal areas. Rigorous testing on animal models demonstrated its safety, stability, and ability to deliver therapeutic agents without damaging tissue.
Results showed bioavailability comparable to subcutaneous injections, with up to 82% absorption for siRNA and 67% for GLP-1 in pigs. The system’s dual-nozzle design minimized recoil, enhancing stability and precision during administration.
This breakthrough platform could revolutionize oral drug delivery, offering a safe, effective, and convenient alternative for delivering large-molecule therapies while eliminating the need for needles.